Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.37 |
| ▸ | PIM1 | P11309 | 8/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 7/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29268973 | 1.00 | HDAC1 (0.37) | HDAC1HDAC6PIM1SLC5A1FPR2 | |
| SCHEMBL29268975 | 1.00 | HDAC1 (0.37) | HDAC1HDAC6PIM1SLC5A1FPR2 | |
| SCHEMBL25215127 | 0.92 | HDAC1 (0.39) | HDAC1HDAC6PIM1PIM2 | |
| SCHEMBL30474032 | 0.89 | HDAC1 (0.37) | HDAC1HDAC6PIM1SLC5A1PIM2 | |
| SCHEMBL30061997 | 0.87 | HDAC1 (0.41) | HDAC1HDAC6PIM1SLC5A1 | |
| SCHEMBL30062624 | 0.87 | HDAC1 (0.41) | HDAC1HDAC6PIM1SLC5A1 | |
| SCHEMBL29268952 | 0.87 | DGAT2 (0.39) | HDAC1HDAC6PIM1SLC5A1 | |
| SCHEMBL29269017 | 0.87 | HDAC1 (0.37) | HDAC1HDAC6PIM1 | |
| SCHEMBL29269016 | 0.87 | HDAC1 (0.37) | HDAC1HDAC6PIM1 | |
| SCHEMBL30473939 | 0.87 | HDAC1 (0.37) | HDAC1HDAC6PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034122-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2025-01-30 | — | — | US | disclosed |
| EP-4441044-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| CN-118302422-A | Substituted N-cyanopyrrolidines having activity as USP30 inhibitors | 特殊治疗有限公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2023099561-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034122-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP47, USP1 | HDAC1 560/4885HDAC6 764/4885PIM1 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.